Compass Pathways (MEX:CMPSN) Issuance of Debt: MXN335.08 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:CMPSN Compass Pathways PLC MEX:CMPSN
12 GF Score
Price MXN242.00
! 1 Warning Sign
View Full Analysis

What is Compass Pathways Issuance of Debt?

Compass Pathways MEX:CMPSN 12 Issuance of Debt is MXN335.08 Mil as of Jun. 2026. GuruFocus rates MEX:CMPSN with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Compass Pathways's Issuance of Debt for the three months ended in Jun. 2026 was MXN0.00 Mil.

Compass Pathways's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was MXN335.08 Mil.

Compass Pathways Issuance of Debt Related Terms

Compass Pathways Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Compass Pathways's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Pathways Issuance of Debt Chart

Compass Pathways Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial 0.00 0.00 502.18 0.00 0.00

Compass Pathways Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 335.08 0.00
MEX:CMPSN
12GF Score
Compass Pathways PLC MEX:CMPSN
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Pathways Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN335.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of MXN335.08 Mil mean?
Compass Pathways (MEX:CMPSN) has a Issuance of Debt of MXN335.08 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Compass Pathways and its competitors.
Is Compass Pathways' Issuance of Debt too high?
Compass Pathways' current Issuance of Debt is MXN335.08 Mil. Overall, Compass Pathways has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' Issuance of Debt compare to ARDT and HCSG?
Compass Pathways' Issuance of Debt of MXN335.08 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Healthcare Providers & Services company?
A good Issuance of Debt depends on the Healthcare Providers & Services industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Compass Pathways and its competitors. Compass Pathways's current Issuance of Debt is MXN335.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (MEX:CMPSN) has a current Issuance of Debt of MXN335.08 Mil. The current Issuance of Debt is MXN335.08 Mil. Compass Pathways' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Compass Pathways (MEX:CMPSN), the current Issuance of Debt is MXN335.08 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Pathways Business Description

Other Exchanges CMPS:USA5Y6:Germany
Address 33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
12GF Score

Get the complete analysis for MEX:CMPSN

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN242.00
Price